SIC
ZVRA icon

SJS Investment Consulting’s Zevra Therapeutics ZVRA Stock Holding History

SJS Investment Consulting’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$27 – 2586
2025
Q4 		$27 Buy
+3
New +$28 ﹤0.01% 2058

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

SJS Investment Consulting's ZVRA Position: Q1 2026 in Review

SJS Investment Consulting sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 3 shares — an estimated $27 sold.

SJS Investment Consulting first reported a position in ZVRA in Q4 2025 and held it in 1 quarter. The position peaked at $27 in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • SJS Investment Consulting reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 3 Zevra Therapeutics shares in Q1 2026, an estimated $27.
  • SJS Investment Consulting first reported a position in Zevra Therapeutics in Q4 2025 and held it in 1 quarter.
  • SJS Investment Consulting's Zevra Therapeutics position peaked at $27 in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.